DCM
APGE icon

Driehaus Capital Management’s Apogee Therapeutics APGE Stock Holding History

Driehaus Capital Management’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$231M Sell
1,740,101
-180,699
-9% -$16.3M 1.34% 8
2026
Q1 		$162M Sell
1,920,800
-262,904
-12% -$19.1M 1.19% 7
2025
Q4 		$165M Buy
2,183,704
+25,202
+1% +$1.59M 1.12% 7
2025
Q3 		$85.8M Sell
2,158,502
-152,253
-7% -$5.81M 0.61% 39
2025
Q2 		$100M Sell
2,310,755
-28,808
-1% -$1.1M 0.8% 22
2025
Q1 		$87.4M Sell
2,339,563
-265,747
-10% -$10.3M 0.84% 21
2024
Q4 		$118M Buy
2,605,310
+71,703
+3% +$3.66M 0.97% 16
2024
Q3 		$149M Buy
2,533,607
+415,737
+20% +$19.9M 1.28% 10
2024
Q2 		$83.3M Buy
2,117,870
+54,107
+3% +$2.63M 0.81% 27
2024
Q1 		$137M Buy
2,063,763
+734,699
+55% +$32.1M 1.37% 9
2023
Q4 		$37.1M Sell
1,329,064
-10,211
-0.8% -$205K 0.45% 63
2023
Q3 		$28.5M Buy
+1,339,275
New +$29.5M 0.37% 83

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Driehaus Capital Management's APGE Position: Q2 2026 in Review

Driehaus Capital Management reduced its Apogee Therapeutics (APGE) stake by 9.4% in Q2 2026, selling an estimated $16.3M and leaving 1,740,101 shares worth $231M. The position accounts for 1.34% of the portfolio, ranked #8.

Driehaus Capital Management first reported a position in APGE in Q3 2023 and has held it in 12 quarters since. 288 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • Driehaus Capital Management held 1,740,101 shares of Apogee Therapeutics worth $231M as of Q2 2026.
  • Driehaus Capital Management sold 180,699 Apogee Therapeutics shares in Q2 2026, an estimated $16.3M.
  • Apogee Therapeutics made up 1.34% of Driehaus Capital Management's portfolio in Q2 2026, its #8 holding.
  • Driehaus Capital Management first reported a position in Apogee Therapeutics in Q3 2023 and has held it in 12 quarters since.
  • 288 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Driehaus Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.